Plain-English translation of NCT07202000 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new therapy called KER-012, which works by blocking a protein that may contribute to heart failure. Researchers believe KER-012, combined with a personalized exercise program, might help people with a specific type of heart failure exercise longer and improve thinking and memory. The study will compare the new treatment to a placebo (inactive injection) over 6 months.
People with this type of heart failure often struggle with exercise capacity and memory problems, and current treatments don't fully address these challenges. This trial is testing whether blocking a specific protein could improve both physical fitness and brain function in these patients.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic at the start, at 12 weeks, and at 24 weeks for heart tests, exercise tests, blood work, memory tests, and physical measurements. For the first 12 weeks, you'll receive either the new therapy or a placebo injection (by chance, 50/50), plus a personalized exercise plan. At week 12, you'll switch to whichever treatment you didn't receive in the first half, and continue exercising for another 12 weeks. Throughout, researchers will track your exercise ability, strength, memory, and how you feel.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States